<DOC>
	<DOCNO>NCT00003140</DOCNO>
	<brief_summary>RATIONALE : Estrogen stimulate growth breast cancer cell . Hormone therapy use letrozole may fight breast cancer reduce production estrogen . PURPOSE : This randomized phase III trial study letrozole see well work treat woman breast cancer receive tamoxifen least 5 year .</brief_summary>
	<brief_title>Letrozole After Tamoxifen Treating Women With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare disease-free survival overall survival postmenopausal woman primary breast cancer complete least five year adjuvant aromatase inhibitor initial therapy tamoxifen treat letrozole placebo . Secondary - Compare incidence contralateral breast cancer patient treat regimen . - Evaluate long-term clinical laboratory safety letrozole , term lipid profile , cardiovascular morbidity mortality , incidence bone fracture , change bone density , common toxic effect , patient population . - Compare quality life patient treat regimen . Re-randomization Primary - Compare disease-free survival patient , receive least 4.5 year letrozole , re-randomized receive additional 5 year letrozole v placebo . Secondary - Determine whether common genetic polymorphism gene encode protein involve pharmacokinetic and/or pharmacodynamic pathway letrozole contribute individual variation toxicity efficacy letrozole therapy . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord receptor status ( positive v unknown ) , lymph node status ( negative v positive v unknown ) , prior adjuvant chemotherapy ( yes v ) , interval last dose aromatase inhibitor therapy randomization ( &lt; 6 month vs 6 months-2 year ) , duration prior tamoxifen use ( 0 year vs &lt; 2 year vs 2-4.5 year vs &gt; 4.5 year ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral letrozole daily . - Arm II : Patients receive oral placebo daily . In arm , treatment continue 5 year absence disease progression unacceptable toxicity . Patients arm II may offer oral letrozole daily 5 year . Quality life assess baseline , 6 month , annually 4.5 year . - Double-blind , re-randomization : Patients complete ≥ 4.5 year letrozole ( arm I ) experience recurrent disease new primary breast cancer , include ductal carcinoma situ , may participate double-blind , placebo-controlled , re-randomization portion study . Patients stratify accord lymph node status enrollment ( negative v positive v unknown ) , prior adjuvant chemotherapy ( yes v ) , interval last dose letrozole re-randomization ( &lt; 6 month vs 6 month 2 year ) . Common genetic single nucleotide polymorphism gene encode protein involve pharmacokinetic and/or pharmacodynamic pathway letrozole analyze order determine single nucleotide polymorphism contribute individual variation toxicity efficacy letrozole therapy . Quality life assess first randomization . Patients follow annually . PROJECTED ACCRUAL : A total 4,700 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm primary invasive breast carcinoma resect time original diagnosis No ductal carcinoma situ Axillary lymph node negative , positive , unknown No evidence metastases No localized distant breast cancer recurrence Not register protocol NCCTG893052 , IBCSG protocol , protocol SWOGS9623 Hormone receptor status : Estrogen progesterone receptor positive define tumor receptor content least 10 fmol/mg protein receptor positive ERICA PgRICA Unknown status allow effort determine status make immunocytochemistry No contralateral breast cancer PATIENT CHARACTERISTICS : Age : Postmenopausal Sex : Female Menopausal status : Postmenopausal define one following : Age 50 start adjuvant tamoxifen Under age 50 consider postmenopausal treat physician start adjuvant tamoxifen Under age 50 start adjuvant tamoxifen bilateral oophorectomy ( surgical radiation ) Under age 50 premenopausal start adjuvant tamoxifen , become amenorrheic tamoxifen remain amenorrheic least 1 year Considered postmenopausal physician LH/FSH level treatment center 's postmenopausal limit Performance status : ECOG 02 Life expectancy : At least 5 year Hematopoietic : WBC ≥ 3,000/mm^3 OR Granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic : AST and/or ALT &lt; 2 time upper limit normal ( ULN ) ( unless image examination rule metastatic disease ) Alkaline phosphatase &lt; 2 time ULN ( unless image examination rule metastatic disease ) Renal : Not specify Other : No concurrent medical psychiatric condition would preclude study participation No malignancy within past 5 year except adequately treat superficial squamous cell basal cell skin cancer carcinoma situ cervix Able swallow study drug Adequate oral intake PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Prior adjuvant chemotherapy allow No concurrent chemotherapy Endocrine therapy : Completed least 4.5 6 year adjuvant tamoxifen resection Completed least 4.56 year adjuvant aromatase inhibitor initial therapy tamoxifen No 3 month since prior adjuvant tamoxifen No concurrent hormone replacement therapy ( e.g. , megestrol ) No concurrent selective estrogenreceptor modulators ( e.g. , raloxifene idoxifene ) Concurrent intermittent vaginal estrogen ( e.g. , Estring ) allow local measure intractable vaginal atrophy insufficient No concurrent aromatase inhibitors No 2 year since prior aromatase inhibitor therapy ( rerandomization ) Radiotherapy : Prior radiotherapy allow Surgery : See Disease Characteristics Other : At least 1 month since prior investigational drug Prior treatment clinical trial breast cancer allow permission obtain sponsor original study patient participate MA.17/JMA.17/BIG9701 No prior placebo core protocol No concurrent anticancer therapy Concurrent thyroid medication , calcium , vitamin D , bisphosphonates allow</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>